Mark has led much of the seminal work on fecal transplantation and the human microbiome, publishing in leading journals such as Nature and NEJM. He translated fecal transplantation from a topic of research into clinical practice by founding OpenBiome, where he pioneered the universal donor model as a safe, effective and cost-efficient solution to the C. difficile epidemic. Under Mark's leadership, OpenBiome has treated more than 20,000 patients through a network of over 800 hospitals. He co-founded Finch Therapeutics to develop defined microbial therapies that treat diseases beyond C.difficile.
Mark graduated summa cum laude from Princeton University with a BA in Biology and received his Ph.D. in Microbiology from MIT.
Before co-founding Finch, Andrew helped grow OpenBiome as its Operations Director. Andrew joined OpenBiome after working as a consultant for Bain & Company in Chicago. At Bain, Andrew served clients across several industries, including healthcare, manufacturing, telecom, consumer packaged goods, airlines, retail, and insurance while working across multiple services including growth strategy, performance improvement, negotiations, M&A, and IT. Prior to joining Bain, Andrew worked in investment banking at JPMorgan.
Andrew holds a BBA with High Distinction from the Ross School of Business at the University of Michigan.
Eric Alm, PhD
Eric is a professor of bioengineering at MIT, a member of the Broad Institute, and a Director for the Center for Microbiome Informatics and Therapeutics at MIT. His research uses complementary computational and experimental methods to engineer the human microbiome, including data science, quantitative analysis, and novel molecular techniques.
Eric earned his Bachelors from the University of Illinois (Champaign-Urbana), his Masters from the University of California (Riverside), and his PhD from the University of Washington (Seattle). He held a postdoctoral appointment at the University of California (Berkeley) and Lawrence Berkeley National Lab before joining the faculty at MIT.
Dean Glettig, PhD
Dean previously worked as a postdoctoral fellow in the lab of Bob Langer at MIT, with a particular focus on improving current methods in oral drug delivery. His research was funded by the Swiss National Science Foundation, the Max-Planck Institute, as well as the Bill & Melinda Gates Foundation. This resulted in the filing of 4 patents and the start of a spin-off company.
Dean received his BSc & MSc in Chemistry from ETH Zurich and a PhD in Biomedical Engineering from Tufts University.
Elaine Vo, PhD
Elaine previously directed the Research and Development Program at OpenBiome, characterizing the stability, viability, and potency of existing treatments as well as developing next generation FMT products for both treatment of recurrent C. difficile infection and clinical research on FMT for new indications.
She holds an AB in Organismic and Evolutionary Biology from Harvard University and a PhD in Integrative Biology from the University of California, Berkeley.
Susan Clancy, MBA
Susan has enjoyed a series of Chief Financial Officer roles across organizations that have created or profoundly reshaped their industries. She was a financial leader at two internet pioneers, CNET and ZDNET. Both were among the top 10 websites in the world during her tenure and were at the vanguard of developing the online advertising business model. She also served as CFO for one of the most respected global development organizations, Accion International. At Accion, she ran finance operations on 5 continents, reshaped their global strategy and laid the groundwork for Accion's Impact Investing division.
Susan received a BS from Cornell University and an MBA from Harvard Business School
Jim Sigler, MBA
Jim has 26 years of experience in drug development. At Genzyme, he and his team brought Carticel™, the first biologic therapy of its type, from academia all the way through FDA submission, inspection, licensure, and commercialization. At Reprogenesis, he and his team executed a crash re-formulation and pre-clinical model development effort that resulted in the resumption of a Phase III trial less than nine months after suspending the trial. At Acceleron, he and his team completed in-house manufacture of the first clinical drug substance for the company, and the outside manufacture of clinical drug product, less than two years after the company’s initial financing and barely seventeen months after board approval to build the in-house capability.
Jim received his BS in Biology/General Studies from Cornell University and his MBA from Harvard Business School.
Sonia Timberlake, PhD
Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunnogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.
Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.
Paige Swanson is the Director of Research Operations at Finch Therapeutics, driving the design and implementation Finch's research platform. Having managed large academic labs at Harvard University and MIT, Paige has designed operational systems which have supported many high impact peer-reviewed publications. In addition, Paige has coordinated the move and setup of laboratories for two newly tenured professors at Harvard. She has extensive experience leveraging robotics to automate and scale-up processes in Microbiology and Molecular Biology. She received her B.S. in Evolutionary Biology from the University of Colorado at Boulder.
Chuck is the Director of Technical and Quality Operations at Finch Therapeutics and oversees the Biologic Manufacturing and Quality teams. He has extensive Manufacturing and Quality experience from biotech companies such as Genzyme, EMD, and Transkaryotic Therapies spanning 15+ years. Chuck is excited to be using this experience to help Finch produce safe and effective therapies for Clinical use. In addition, improving the quality systems used at Finch will ensure that products supplied to our research partners are of the highest quality. Chuck holds dual Bachelors in Biology and Chemistry and a Master’s Degree in Biology from the UMass Lowell.
Josh is the Manager of Business Operations at Finch Therapeutics. He has an undergraduate in public policy from Princeton, and a masters in economic and social history from Oxford University. Josh has worked for non-profits, consulting firms, and Canada's Minister of Foreign Affairs. He looks forward to ensuring that Finch's scientists and researchers have the support they need to advance their research.
Brian has 10 years of biologic drug development experience. Brian joins Finch from Acceleron Pharma, where he held multiple different functions including CMC, Regulatory, Clinical, and Business Development. At Acceleron, Brian was involved in shepherding multiple molecules through all stages of the drug development process.
Brian holds a BS in Biochemistry from Northeastern University.
Eva de la Serna
Eva is a Product Development Research Associate at Finch Therapeutics, where she works with a multidisciplinary team to develop novel drug delivery devices for microbiome-inspired therapeutics. Previously, Eva has worked at The Estée Lauder Companies and Professor Langer's Laboratory for Drug Delivery and Tissue Engineering at MIT. She holds a Bachelors degree in Chemical Engineering from MIT.
Thomas Mitchell is the Program Manager helping drive Finch's lead therapeutic program, FIN-403. Thomas has extensive experience from a diverse background, ranging from Program Management to Microbiology to Data Analysis.
Thomas was previously an Officer in the Australian Army. He graduated as a Lieutenant from the esteemed Royal Military College for Officers in Australia. After his tenure, Thomas moved away from strategic operational work to pursue a career in Life Sciences. He completed his masters in computational biology before pursuing a PhD at the University of Queensland, also in computational biology, with a focus on infectious disease. During this time, his work focused on building systems to understand and track drug-resistant pathogens. Concurrently, he worked for a branch of Sonic Health, where he pioneered diagnostic analysis methods in order to track drug-resistant infectious disease in the Australian population. Overall, sitting at the intersection between multiple disciplines has enabled Thomas to be a driving force in Finch’s therapeutic pipeline.
Kevin Roelofs, PhD
Kevin Roelofs is a microbiologist, trained in the use of molecular genetics, biochemistry, and comparative genomics to characterize microbial life. Kevin graduated with a BS in Biology from William and Mary, and received his PhD in Cell Biology and Molecular Genetics from the University of Maryland where he studied nucleotide signaling systems with Dr. Vincent Lee. Prior to joining Finch, Kevin’s interest in microbial ecology led him to a postdoctoral fellowship in Dr. Laurie Comstock’s lab at Harvard Medical School. There he identified mechanisms of inter-bacterial competition that influence strain-level composition of the human gut microbiota. At Finch, Kevin leads the Microbiology team in the culture, isolation, and characterization of the human gut microbiota, and supports development of Finch’s intellectual property.
Jessica Pierce, PhD
Jessica Pierce is a Research Scientist interested in the mechanisms of microbe-host interactions, particularly within the gut microbiome. She received her PhD from the Sackler School at Tufts University in Molecular and Microbiology. Dr. Pierce studied gastrointestinal colonization of the pathogenic yeast Candida albicans and proposed a novel model of 'immunosensing' in the gut. Dr. Pierce then continued as a Postdoctoral Fellow at the National Institutes of Health to study enterotoxigenic strains of Bacteroides fragilis to identify potential novel drug targets for diarrheal disease and colorectal cancer.
Ylaine Gerardin, PhD
Ylaine is a Data Scientist at Finch, where she works on building Finch's machine learning platform for generating ecological insights from fecal transplant data. Previously, she worked on engineered microbial communities at Harvard, where she received a PhD in Systems Biology. She holds dual BS degrees in Electrical Engineering and Biology from MIT.
Tom is a Research Technician on the Molecular Microbiology team, where he designs assays that quantitatively assess therapeutically-relevant microbial metabolites. His previous scientific work was also centered around stool: studying the confluence of paleoclimate and human history through fecal metabolites in lake sediments from Norse settlers in Eastern Greenland. Tom graduated from UMass Amherst with a B.S. in Chemistry.
Rotem Gura Sadovksy, PhD
Rotem has a deep background in creating statistical tools to model data for applications in biology. He has accumulated experience in data science from within and outside biology since 2003. Rotem graduated from the Hebrew University in Jerusalem with a B.Sc. in physics and received his Ph.D. in computational and systems biology from MIT.
Deirdre is the Manager of Quality at Finch Therapeutics and oversees the Quality team. Her previous experience includes quality assurance roles at biotech and clinical research organizations, clinical trial management for a medical device start up as well as over 5 years as a metrology technician in the defense, aerospace, biotech and pharmaceutical industries. Deirdre earned her Bachelor’s degree in Technology Management from Saint Leo University while serving on active duty in the United States Air Force. She is pursuing a Master’s in Project Management with a specialization in Clinical Trial Design at Northeastern University and will graduate in December 2016.
Deirdre is passionate about the delivery of breakthrough therapies to patients suffering from conditions for which no effective treatment is currently available.
Kurt is a Quality Supervisor at Finch Therapeutics. He is a graduate of University of Vermont, with a B.S. in Biological Sciences and a focus in microbiology. From a young age, he has been interested in connecting business applications to the healthcare system, and Finch has been a way for him to bridge those interests. Kurt is excited to be a part of Finch because its continuing impact on FMT and microbiome research is something that many patients will benefit from. Kurt plans to help further develop Finch's FMT production pipeline, and to assist in quality assurance procedures as Finch continues to reach more patients in need.
Annie is a Research Associate on the Molecular Microbiology team, designing assays to assess therapeutic potential of Finch's defined microbial products. Much of her early career has focused on high-throughput screening of avian influenza samples, assaying candidate compounds for drug development in neurodegenerative diseases, and isolation and analysis of samples from the skin microbiome. Annie graduated from MIT with a Bachelor's of Science in Biological Engineering.
John is a research associate on the molecular microbiology team designing assays to quantitatively assess the therapeutic attributes of isolated microbes. His previous scientific work has included characterizing and improving the uptake and cytosolic access of potentially therapeutic proteins. John received his Bachelor's of science from Brandeis University and his Master's of science degree from Yale University.
Manjot is a Research Associate at Finch Therapeutics. During her undergraduate research, Manjot worked in Dr. Klepac-Ceraj’s Microbial Ecology lab and focused on understanding the interplay between high-fat diet, estradiol and the female mouse gut microbiota. She graduated from Wellesley College with a Bachelor of Arts in Biochemistry.
Delasie has 7 years of biotechnology manufacturing experience. Delasie joins Finch from Histogenics, a regenerative therapies company, where he gained expertise in manufacturing in cell culture of an autologous chondrocyte product. He also brings vast knowledge of Phase III clinical trial production.
Delasie attended Boston University where he studied biomedical sciences.
Sarah is a Lead Biomanufacturing Associate at Finch Therapeutics. She is a graduate of the University of New Haven where she earned her B.S. in Forensic Science and Biology. She gained interest in the field after learning about fecal transplants from her microbiology professor. She is excited to be a part of the biomanufacturing team and eager to see where FMT will be utilized in the future.
Eric is a Lead Associate in the Biomanufacturing Department. He studied Physics and Chemistry at the University of Massachusetts, and conducted nuclear physics research for several years during this time. He also has experience in research development, intellectual property management, and high school science education. Eric’s other interests music composition, endurance athletics, and orthomolecular medicine. He hopes to extend his knowledge in the life sciences while contributing to Finch’s mission of increasing safe access to FMT.
Wendy is a Research Technician on the Molecular Microbiology team at Finch Therapeutics. She completed her undergraduate degree in Biochemistry at Eastern Nazarene College and earned a Master in Cell and Molecular Biology from Long Island University. Her previous research focused on endocrinology, diabetes and hypertension at Brigham and Women's Hospital and newborn lung disease at Tufts Medical Center.
Kelsey O'Brien, MPH
Kelsey is the Director of Clinical Operations at Finch Therapeutics. Passionate about leveraging behavioral insights to create a healthier world, she completed her undergraduate degree in Psychology at Colby College and earned a Master of Public Health from Harvard University. Kelsey has extensive experience with mixed method research. Prior to joining Finch, she conducted clinical research at Massachusetts General Hospital, marketing research at Yale University, and infectious disease research with the US Navy in Cusco, Peru.
Kelly is the Clinical Program Lead at Finch Therapeutics, where she manages both stool donors and donor assistants. She oversees aspects of the clinical program including protocol adherence, screening cadence, and development of safety systems and protocols. Kelly has previous research experience in clinical neurophysiology and global health economics. She holds a dual degree in Biology and Economics from Colby College.
Jenny Goldberg, RN BSN
Jenny is a Clinical Nurse at Finch Therapeutics. She graduated from Northeastern University with Bachelor’s degrees in both nursing and biology. With several years of experience in records and data management, clinical research and development, and patient education, Jenny is excited to combine her research and nursing knowledge while maintaining the donor screening program at Finch.
Jill Marshall, BSN
Zac is the Donor Recruitment Specialist at Finch Therapeutics. Zac is a recent graduate form the University of Alabama at Birmingham, where he studied kinesiology and nutrition. He is excited to deploy his communication skills to recruit people for Finch's stool donation program.
Daniel Geng is a Quality Assurance Associate at Finch Therapeutics. He graduated from Stony Brook University (SUNY) with a double major in Biomedical Engineering and Applied Math/Statistics. He has had previous internship experiences in Quality Assurance and Quality Control within the field of biotech, and seeks to further explore what the industry has to offer. Daniel is excited to join the growing Quality team at Finch, and to contribute to providing innovative and safe care to more patients in need.
Zhen is a Fulfillment Assistant at Finch Therapeutics. He is a recent graduate of Northeastern University, where he studied computational chemistry and computational biology. His previous works include predicting the functionally important residues in protein structures and rating protein evaluation metrics. Finch is a new beginning for him. Zhen's goal is to help patients suffering from C. difficile receive timely treatments.
Mariia is the Internal Operations and Communications Coordinator at Finch Therapeutics, where she oversees office operations and assists the executive team. She is a recent graduate from Boston University, where she received a BA in Sociology. Having experience at various organizations in the States and abroad, Mariia is excited to join Finch and support microbiome research and development.
Maddie is a Clinical Research Technician at Finch Therapeutics. She graduated in June from the University of Chicago with a BA in the biological sciences with a specialization in neuroscience. In her studies and previous work, she has sought to better the human experience by looking for more just and equitable health care solutions based off of knowledge of both biology and social forces at play and is passionate about investing in alternative approaches to medicine. At Finch, she is excited to continue these pursuits to the fullest.
At home, she has been cultivating her own ecological community, tending to a verdant succulent garden and two cats. In her free time, she enjoys playing rugby and ice hockey, drinking coffee, and reading sociology, autobiography, and fiction.
Suja is a Biomanufacturing Associate at Finch Therapeutics. She is a graduate from Bharathidasan University (India), where she received her M.Phil (Master of Philosophy) degree in Radiation and Nuclear Physics. She also graduated from Manonmaniam Sundaranar University (India), where she received her Bachelors and Masters in Physics. She has always been passionate about life science and caring for others. She is excited to learn more about the human microbiome.
Meyling is a Biomanufacturing Associate at Finch Therapeutics. She graduated from Merrimack College having majored in Pre-Med Health Science and minored in Biology and Chemistry. As an undergraduate, she obtained valuable lab skills and experiences that range from organic chemistry, microbiology, to pathophysiology. Prior to Finch, Meyling worked as a behavioral therapist with autistic children. She is eager to learn more and help catalyze research of the microbiome, gain additional lab skills and hopes to assist in developing other research initiatives to help others safely access FMT.
Zain Kassam, MD MPH FRCPC
Dr. Zain Kassam is a gastroenterologist, internal medicine physician and epidemiologist.
Zain was named a Top 40 Under 40 Healthcare Innovator by MedTech and is a Scientific Advisory Board member for the American Gastroenterological Association Center for Gut Microbiome Research & Education. Dr. Kassam's research focuses on innovative microbiome-directed therapies that deeply impact human health and disease. He has authored over 100 peer-reviewed abstracts, publications and book chapters and holds grants from the CDC, CCFA and private foundations.
Dr. Kassam received his MPH degree with a focus on Clinical Trials at Harvard University on a Frank Knox Fellowship and completed his post-doctoral training in microbiome engineering at MIT. He completed both his Internal Medicine and Gastroenterology training at McMaster University, where he was the Chief Medical and Chief Gastroenterology Resident and was awarded the National Resident Leadership Award by the Royal College of Physicians and Surgeons of Canada.
Jessica Allegretti, MD MPH
Dr. Allegretti is a gastroenterologist at Brigham and Women’s Hospital with both clinical and research interests in Clostridium difficile infection and inflammatory bowel disease. She founded and coordinates the fecal transplant program for recurrent Clostridium difficile infections at BWH. She completed her internal medicine residency at Massachusetts General Hospital and her fellowship in gastroenterology at Brigham and Women’s Hospital. She also completed her Master’s in Public Health at Harvard T.H. Chan School of Public Health.
Sanjay is a Clinical Associate at Finch Therapeutics. He recently graduated from Princeton University with a B.A. in Ecology and Evolutionary Biology and a Certificate in Global Health and Health Policy. He is passionate about community-based approaches to public health, which has led him to work with a New Jersey non-profit specializing in HIV/AIDS support services and conduct independent research on new approaches to vector control of the dengue virus for his senior thesis. He is incredibly excited to serve as a Project55 fellow with the Clinical Assessment and Safety team.
Christian is a Biomanufacturing Associate at Finch Therapeutics. He graduated from Endicott College with a B.S. in Biology/Biotechnology (Pre-Professional). Christian interned at Daedalus Software Inc. where he worked on a clinical research data management software. He became interested in solving public health problems in college, leading him to write his thesis on genetic immunity to the dengue virus. Now, Christian is excited to be part of Finch's biomanufacturing team.
Ben Ngai is a Biomanufacturing Associate at Finch Therapeutics. He graduated from Villanova University with a B.S in Environmental Science and Geography. Previously interned and worked at TechEn Inc. as a programmer, Ben is excited to be a part of the Biomanufacturing team. He hopes to contribute to Finch Therapeutics' mission of catalyzing research into the human microbiome and providing safe access to FMT for patients around the world.
Nancy Dubois, MSN, MBA
Kelsey Schilperoort is a donor assistant at Finch Therapeutics. She earned a B.S. in Engineering, concentrating in Bioengineering, from the Olin College of Engineering in Needham Massachusetts, but is now pursuing a degree in medical lab technology at Bunker Hill Community College. Kelsey plans to eventually specialize in medical microbiology.
Amanda Gentile, MRes
Amanda is a biotech professional with 10 years of clinical research experience. Prior to joining Finch Therapeutics, Amanda led clinical trials predominantly in the CNS and Metabolic disease areas. Amanda’s direct trial management experience includes Phase I (2 trials), Phase II (1 global trial), and Phase III (1 US-only, 5 global trials).
In her previous roles, Amanda worked closely with leadership team members to drive and monitor various aspects of clinical development including protocol design, outsourcing and vendor management strategies, clinical site relationship management, and all aspects clinical study planning, execution, and final results reporting.
Amanda holds a BA in Psychology from the College of the Holy Cross and a Master’s of Research Methods in Psychology (MRes) from the University of York.
John Parkinson, PhD
Marina Santiago, PhD
Marina is a Research Scientist at Finch Therapeutics. For the last 10 years, Marina has worked on different aspects of antibiotic resistance, from natural product discovery and isolation, to developing genomics techniques for identifying new resistance factors. She has presented her work at Gordon conferences, national meetings, and to the public through the Harvard Science in the News and the Boston Museum of Science. She received her BS in Molecular Biophysics and Biochemistry from Yale University, and her PhD in Chemical Biology from Suzanne Walker’s lab at Harvard Medical School. She is excited to be at Finch and to apply her multidisciplinary experiences to the challenges of developing microbiome remediation therapeutics.
Steven Smriga, PhD
Jackson Lee, PhD
Jackson is a research scientist and engineer specializing in the bioinformatics of biological systems (e.g. complex bacterial communities and ecologies) for biotechnology, particularly integrating laboratory and clinical studies with 'omics techniques. Previously he has conducted research at NASA Ames Research Center and MIT Lincoln Laboratory in microbial ecology for bioenergy, biodefense, and biomedical applications.
Jackson obtained his BS in Mechanical Engineering From Rice University and his PhD in Environmental Science and Engineering from the Colorado School of Mines.
Jacob is a Data Analyst in the Biomanufacturing Department. He studied Biology at Middlebury College in Vermont, and has conducted marine genetics research while in Vermont as well as abroad. He has experience in molecular biology, genomics, and data science. He hopes to extend his knowledge of big data and biological sciences to further the research goals of Finch and improve patient outcomes.
Samantha is a Biomanufacturing Associate at Finch. She is a recent graduate of the University of Rochester with dual degrees in microbiology and business administration. Samantha previously worked at a medical device company with a non-pharmaceutical treatment for Alzheimer’s disease, as well as at a non-profit catalyzing research into Multiple Sclerosis.
Marilyn Crump is a donor assistant at Finch Therapeutics. She earned a Bachelor's degree in philosophy from Murray State University in Kentucky. She currently works as a mental health counselor in addition to her role at Finch. She plans to eventually receive her Masters in Mental Health Counseling.